Skip to Main content Skip to Navigation
Journal articles

Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials

Abstract : The mortality of hepatocellular carcinoma (HCC) is quickly increasing worldwide. In unresectable HCC, the cornerstone of systemic treatments is switching from tyrosine kinase inhibitors to immune checkpoints inhibitors (ICI). Next to ICI, adoptive cell transfer represents another promising field of immunotherapy. Targeting tumor associated antigens such as alpha-fetoprotein (AFP), glypican-3 (GPC3), or New York esophageal squamous cell carcinoma-1 (NY-ESO-1), T cell receptor (TCR) engineered T cells and chimeric antigen receptors (CAR) engineered T cells are emerging as potentially effective therapies, with objective responses reported in early phase trials. In this review, we address the biological rationale of TCR/CAR engineered T cells in advanced HCC, their mechanisms of action, and results from recent clinical trials.
Document type :
Journal articles
Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-03689931
Contributor : Philippe ROCHIGNEUX Connect in order to contact the contributor
Submitted on : Tuesday, June 7, 2022 - 4:46:44 PM
Last modification on : Wednesday, June 8, 2022 - 2:59:20 PM

Links full text

Identifiers

Collections

Citation

Philippe Rochigneux, Brice Chanez, Bernadette de Rauglaudre, Emmanuel Mitry, Christian Chabannon, et al.. Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. Cancers, MDPI, 2021, 13 (2), pp.271. ⟨10.3390/cancers13020271⟩. ⟨hal-03689931⟩

Share

Metrics

Record views

5